Personal information

Websites & social links

LinkedIn Profile

Other IDs

Scopus Author ID: 57191586183
Loop profile: 222592

Keywords

Cancer Immunotherapy

Countries

United Kingdom

Activities

Collapse all

Employment (3)

University of Cambridge: Cambridge, Cambridgeshire, GB

2020-06-01 to present | Postdoctoral Research Scientist (Department of Pathology)
Employment
Source: Self-asserted source
Paula Kuo

Babraham Institute: Cambridge, Cambridgeshire, GB

2019-04-23 to 2020-05-31 | Postdoctoral Research Scientist (Lymphocyte signaling and development)
Employment
Source: Self-asserted source
Paula Kuo

The University of Queensland: Saint Lucia, QLD, AU

2018-07-13 to 2018-12-13 | Research Officer (Translational Research Institute)
Employment
Source: Self-asserted source
Paula Kuo

Education and qualifications (1)

University of Queensland: Brisbane, QLD, AU

2015-04-13 to 2018-12-07 | Doctor of Philosophy (Diamantina Institute, Faculty of Medicine)
Education
Source: Self-asserted source
Paula Kuo

Professional activities (2)

British Society for Immunology: Cambridge, GB

2019-05 to present
Membership
Source: Self-asserted source
Paula Kuo

Australasian Society for Immunology : Brisbane, AU

2015-04 to 2019-12
Membership
Source: Self-asserted source
Paula Kuo

Works (45)

Data from IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy

2025-03-28 | Preprint
DOI: 10.1158/2767-9764.c.7397857
Contributors: Charlotte J. Imianowski; Paula Kuo; Sarah K. Whiteside; Teresa von Linde; Alexander J. Wesolowski; Alberto G. Conti; Alexander C. Evans; Tarrion Baird; Benjamin I. Morris; Nicole E. Fletcher et al.
Source: check_circle
Crossref

Supplementary Figure 1 from IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy

2025-03-28 | Preprint
DOI: 10.1158/2767-9764.28688635
Contributors: Charlotte J. Imianowski; Paula Kuo; Sarah K. Whiteside; Teresa von Linde; Alexander J. Wesolowski; Alberto G. Conti; Alexander C. Evans; Tarrion Baird; Benjamin I. Morris; Nicole E. Fletcher et al.
Source: check_circle
Crossref

Supplementary Figure 2 from IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy

2025-03-28 | Preprint
DOI: 10.1158/2767-9764.28688632
Contributors: Charlotte J. Imianowski; Paula Kuo; Sarah K. Whiteside; Teresa von Linde; Alexander J. Wesolowski; Alberto G. Conti; Alexander C. Evans; Tarrion Baird; Benjamin I. Morris; Nicole E. Fletcher et al.
Source: check_circle
Crossref

Supplementary Figure 3 from IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy

2025-03-28 | Preprint
DOI: 10.1158/2767-9764.28688629
Contributors: Charlotte J. Imianowski; Paula Kuo; Sarah K. Whiteside; Teresa von Linde; Alexander J. Wesolowski; Alberto G. Conti; Alexander C. Evans; Tarrion Baird; Benjamin I. Morris; Nicole E. Fletcher et al.
Source: check_circle
Crossref

Supplementary Figure 1 from IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy

2024-09-17 | Preprint
DOI: 10.1158/2767-9764.27046095.v1
Contributors: Charlotte J. Imianowski; Paula Kuo; Sarah K. Whiteside; Teresa von Linde; Alexander J. Wesolowski; Alberto G. Conti; Alexander C. Evans; Tarrion Baird; Benjamin I. Morris; Nicole E. Fletcher et al.
Source: check_circle
Crossref

Supplementary Figure 1 from IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy

2024-09-17 | Preprint
DOI: 10.1158/2767-9764.27046095
Contributors: Charlotte J. Imianowski; Paula Kuo; Sarah K. Whiteside; Teresa von Linde; Alexander J. Wesolowski; Alberto G. Conti; Alexander C. Evans; Tarrion Baird; Benjamin I. Morris; Nicole E. Fletcher et al.
Source: check_circle
Crossref

Supplementary Figure 2 from IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy

2024-09-17 | Preprint
DOI: 10.1158/2767-9764.27046092.v1
Contributors: Charlotte J. Imianowski; Paula Kuo; Sarah K. Whiteside; Teresa von Linde; Alexander J. Wesolowski; Alberto G. Conti; Alexander C. Evans; Tarrion Baird; Benjamin I. Morris; Nicole E. Fletcher et al.
Source: check_circle
Crossref

Supplementary Figure 2 from IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy

2024-09-17 | Preprint
DOI: 10.1158/2767-9764.27046092
Contributors: Charlotte J. Imianowski; Paula Kuo; Sarah K. Whiteside; Teresa von Linde; Alexander J. Wesolowski; Alberto G. Conti; Alexander C. Evans; Tarrion Baird; Benjamin I. Morris; Nicole E. Fletcher et al.
Source: check_circle
Crossref

Supplementary Figure 3 from IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy

2024-09-17 | Preprint
DOI: 10.1158/2767-9764.27046086
Contributors: Charlotte J. Imianowski; Paula Kuo; Sarah K. Whiteside; Teresa von Linde; Alexander J. Wesolowski; Alberto G. Conti; Alexander C. Evans; Tarrion Baird; Benjamin I. Morris; Nicole E. Fletcher et al.
Source: check_circle
Crossref

Supplementary Figure 3 from IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy

2024-09-17 | Preprint
DOI: 10.1158/2767-9764.27046086.v1
Contributors: Charlotte J. Imianowski; Paula Kuo; Sarah K. Whiteside; Teresa von Linde; Alexander J. Wesolowski; Alberto G. Conti; Alexander C. Evans; Tarrion Baird; Benjamin I. Morris; Nicole E. Fletcher et al.
Source: check_circle
Crossref

Data from IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy

2024-08-12 | Preprint
DOI: 10.1158/2767-9764.c.7397857.v1
Contributors: Charlotte J. Imianowski; Paula Kuo; Sarah K. Whiteside; Teresa von Linde; Alexander J. Wesolowski; Alberto G. Conti; Alexander C. Evans; Tarrion Baird; Benjamin I. Morris; Nicole E. Fletcher et al.
Source: check_circle
Crossref

Figure 1 from IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy

2024-08-12 | Preprint
DOI: 10.1158/2767-9764.26538481
Contributors: Charlotte J. Imianowski; Paula Kuo; Sarah K. Whiteside; Teresa von Linde; Alexander J. Wesolowski; Alberto G. Conti; Alexander C. Evans; Tarrion Baird; Benjamin I. Morris; Nicole E. Fletcher et al.
Source: check_circle
Crossref

Figure 1 from IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy

2024-08-12 | Preprint
DOI: 10.1158/2767-9764.26538481.v1
Contributors: Charlotte J. Imianowski; Paula Kuo; Sarah K. Whiteside; Teresa von Linde; Alexander J. Wesolowski; Alberto G. Conti; Alexander C. Evans; Tarrion Baird; Benjamin I. Morris; Nicole E. Fletcher et al.
Source: check_circle
Crossref

Figure 2 from IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy

2024-08-12 | Preprint
DOI: 10.1158/2767-9764.26538478.v1
Contributors: Charlotte J. Imianowski; Paula Kuo; Sarah K. Whiteside; Teresa von Linde; Alexander J. Wesolowski; Alberto G. Conti; Alexander C. Evans; Tarrion Baird; Benjamin I. Morris; Nicole E. Fletcher et al.
Source: check_circle
Crossref

Figure 2 from IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy

2024-08-12 | Preprint
DOI: 10.1158/2767-9764.26538478
Contributors: Charlotte J. Imianowski; Paula Kuo; Sarah K. Whiteside; Teresa von Linde; Alexander J. Wesolowski; Alberto G. Conti; Alexander C. Evans; Tarrion Baird; Benjamin I. Morris; Nicole E. Fletcher et al.
Source: check_circle
Crossref

Figure 3 from IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy

2024-08-12 | Preprint
DOI: 10.1158/2767-9764.26538475
Contributors: Charlotte J. Imianowski; Paula Kuo; Sarah K. Whiteside; Teresa von Linde; Alexander J. Wesolowski; Alberto G. Conti; Alexander C. Evans; Tarrion Baird; Benjamin I. Morris; Nicole E. Fletcher et al.
Source: check_circle
Crossref

Figure 3 from IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy

2024-08-12 | Preprint
DOI: 10.1158/2767-9764.26538475.v1
Contributors: Charlotte J. Imianowski; Paula Kuo; Sarah K. Whiteside; Teresa von Linde; Alexander J. Wesolowski; Alberto G. Conti; Alexander C. Evans; Tarrion Baird; Benjamin I. Morris; Nicole E. Fletcher et al.
Source: check_circle
Crossref

Figure 4 from IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy

2024-08-12 | Preprint
DOI: 10.1158/2767-9764.26538472.v1
Contributors: Charlotte J. Imianowski; Paula Kuo; Sarah K. Whiteside; Teresa von Linde; Alexander J. Wesolowski; Alberto G. Conti; Alexander C. Evans; Tarrion Baird; Benjamin I. Morris; Nicole E. Fletcher et al.
Source: check_circle
Crossref

Figure 4 from IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy

2024-08-12 | Preprint
DOI: 10.1158/2767-9764.26538472
Contributors: Charlotte J. Imianowski; Paula Kuo; Sarah K. Whiteside; Teresa von Linde; Alexander J. Wesolowski; Alberto G. Conti; Alexander C. Evans; Tarrion Baird; Benjamin I. Morris; Nicole E. Fletcher et al.
Source: check_circle
Crossref

Figure 5 from IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy

2024-08-12 | Preprint
DOI: 10.1158/2767-9764.26538469
Contributors: Charlotte J. Imianowski; Paula Kuo; Sarah K. Whiteside; Teresa von Linde; Alexander J. Wesolowski; Alberto G. Conti; Alexander C. Evans; Tarrion Baird; Benjamin I. Morris; Nicole E. Fletcher et al.
Source: check_circle
Crossref

Figure 5 from IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy

2024-08-12 | Preprint
DOI: 10.1158/2767-9764.26538469.v1
Contributors: Charlotte J. Imianowski; Paula Kuo; Sarah K. Whiteside; Teresa von Linde; Alexander J. Wesolowski; Alberto G. Conti; Alexander C. Evans; Tarrion Baird; Benjamin I. Morris; Nicole E. Fletcher et al.
Source: check_circle
Crossref

Figure 6 from IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy

2024-08-12 | Preprint
DOI: 10.1158/2767-9764.26538466.v1
Contributors: Charlotte J. Imianowski; Paula Kuo; Sarah K. Whiteside; Teresa von Linde; Alexander J. Wesolowski; Alberto G. Conti; Alexander C. Evans; Tarrion Baird; Benjamin I. Morris; Nicole E. Fletcher et al.
Source: check_circle
Crossref

Figure 6 from IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy

2024-08-12 | Preprint
DOI: 10.1158/2767-9764.26538466
Contributors: Charlotte J. Imianowski; Paula Kuo; Sarah K. Whiteside; Teresa von Linde; Alexander J. Wesolowski; Alberto G. Conti; Alexander C. Evans; Tarrion Baird; Benjamin I. Morris; Nicole E. Fletcher et al.
Source: check_circle
Crossref

Supplementary Figure 1 from IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy

2024-08-12 | Preprint
DOI: 10.1158/2767-9764.26538463
Contributors: Charlotte J. Imianowski; Paula Kuo; Sarah K. Whiteside; Teresa von Linde; Alexander J. Wesolowski; Alberto G. Conti; Alexander C. Evans; Tarrion Baird; Benjamin I. Morris; Nicole E. Fletcher et al.
Source: check_circle
Crossref

Supplementary Figure 1 from IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy

2024-08-12 | Preprint
DOI: 10.1158/2767-9764.26538463.v1
Contributors: Charlotte J. Imianowski; Paula Kuo; Sarah K. Whiteside; Teresa von Linde; Alexander J. Wesolowski; Alberto G. Conti; Alexander C. Evans; Tarrion Baird; Benjamin I. Morris; Nicole E. Fletcher et al.
Source: check_circle
Crossref

Supplementary Figure 2 from IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy

2024-08-12 | Preprint
DOI: 10.1158/2767-9764.26538460
Contributors: Charlotte J. Imianowski; Paula Kuo; Sarah K. Whiteside; Teresa von Linde; Alexander J. Wesolowski; Alberto G. Conti; Alexander C. Evans; Tarrion Baird; Benjamin I. Morris; Nicole E. Fletcher et al.
Source: check_circle
Crossref

Supplementary Figure 2 from IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy

2024-08-12 | Preprint
DOI: 10.1158/2767-9764.26538460.v1
Contributors: Charlotte J. Imianowski; Paula Kuo; Sarah K. Whiteside; Teresa von Linde; Alexander J. Wesolowski; Alberto G. Conti; Alexander C. Evans; Tarrion Baird; Benjamin I. Morris; Nicole E. Fletcher et al.
Source: check_circle
Crossref

Supplementary Figure 3 from IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy

2024-08-12 | Preprint
DOI: 10.1158/2767-9764.26538457.v1
Contributors: Charlotte J. Imianowski; Paula Kuo; Sarah K. Whiteside; Teresa von Linde; Alexander J. Wesolowski; Alberto G. Conti; Alexander C. Evans; Tarrion Baird; Benjamin I. Morris; Nicole E. Fletcher et al.
Source: check_circle
Crossref

Supplementary Figure 3 from IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy

2024-08-12 | Preprint
DOI: 10.1158/2767-9764.26538457
Contributors: Charlotte J. Imianowski; Paula Kuo; Sarah K. Whiteside; Teresa von Linde; Alexander J. Wesolowski; Alberto G. Conti; Alexander C. Evans; Tarrion Baird; Benjamin I. Morris; Nicole E. Fletcher et al.
Source: check_circle
Crossref

IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy

Cancer Research Communications
2024-08-01 | Journal article
DOI: 10.1158/2767-9764.CRC-23-0500
Contributors: Charlotte J. Imianowski; Paula Kuo; Sarah K. Whiteside; Teresa von Linde; Alexander J. Wesolowski; Alberto G. Conti; Alexander C. Evans; Tarrion Baird; Benjamin I. Morris; Nicole E. Fletcher et al.
Source: check_circle
Crossref

CCR8 marks highly suppressive Treg cells within tumours but is dispensable for their accumulation and suppressive function.

Immunology
2021-04-10 | Journal article
DOI: 10.1111/imm.13337
PMID: 33838058
Source: Self-asserted source
Paula Kuo

Manganese-Doped Silica-Based Nanoparticles Promote the Efficacy of Antigen-Specific Immunotherapy.

Journal of immunology (Baltimore, Md. : 1950)
2021-01-27 | Journal article
DOI: 10.4049/jimmunol.2000355
PMID: 33504616
Source: Self-asserted source
Paula Kuo

A cell-based bioluminescence assay reveals dose-dependent and contextual repression of AP-1-driven gene expression by BACH2.

Scientific reports
2020-11-03 | Journal article
DOI: 10.1038/s41598-020-75732-z
PMID: 33144667
PMC: PMC7641119
Source: Self-asserted source
Paula Kuo

BACH2 Drives Quiescence and Maintenance of Resting Treg Cells to Promote Homeostasis and Cancer Immunosuppression

Journal of Experimental Medicine
2020-06-09 | Journal article
DOI: 10.1084/jem.20190711
Source: Self-asserted source
Paula Kuo

A distal enhancer at risk locus 11q13.5 promotes suppression of colitis by Treg cells

Nature
2020-05-13 | Journal article
DOI: 10.1038/s41586-020-2296-7
Part of ISSN: 0028-0836
Part of ISSN: 1476-4687
Source: Self-asserted source
Paula Kuo

A low inflammatory, Langerhans cell-targeted microprojection patch to deliver ovalbumin to the epidermis of mouse skin.

Journal of controlled release : official journal of the Controlled Release Society
2019-03-30 | Journal article
DOI: 10.1016/j.jconrel.2019.03.027
PMID: 30940498
Source: Self-asserted source
Paula Kuo
grade
Preferred source (of 2)‎

Murine HPV16 E7-expressing transgenic skin effectively emulates the cellular and molecular features of human high-grade squamous intraepithelial lesions

Papillomavirus Research
2018 | Journal article
DOI: 10.1016/j.pvr.2017.10.001
EID:

2-s2.0-85036652742
Contributors: Tuong, Z.K.; Noske, K.; Kuo, P.; Bashaw, A.A.; Teoh, S.M.; Frazer, I.H.
Source: Self-asserted source
Paula Kuo via Scopus - Elsevier

Association of local immune suppression in skin with HPV-induced epithelial hyperplasia

2018-12-20 | Dissertation or Thesis
DOI: 10.14264/uql.2019.52
Contributors: Ting-Yu Paula Kuo
Source: check_circle
Crossref

Recruitment of Antigen Presenting Cells to Skin Draining Lymph Node From HPV16E7-Expressing Skin Requires E7-Rb Interaction.

Frontiers in immunology
2018-12-18 | Journal article
DOI: 10.3389/fimmu.2018.02896
PMID: 30619266
PMC: PMC6305623
Source: Self-asserted source
Paula Kuo

The Role of CXCR3 and Its Chemokine Ligands in Skin Disease and Cancer.

Frontiers in Medicine
2018-09-25 | Journal article
DOI: 10.3389/fmed.2018.00271
PMID: 30320116
PMC: PMC6167486
Source: Self-asserted source
Paula Kuo

Batf3 selectively determines acquisition of CD8 + dendritic cell phenotype and function

Immunology and Cell Biology
2017 | Journal article
DOI: 10.1038/icb.2016.83
EID:

2-s2.0-85000419790
Contributors: Chandra, J.; Kuo, P.T.Y.; Hahn, A.M.; Belz, G.T.; Frazer, I.H.
Source: Self-asserted source
Paula Kuo via Scopus - Elsevier

HPV16-E7-specific activated CD8 T Cells in E7 transgenic skin and skin grafts

Frontiers in Immunology
2017 | Journal article
DOI: 10.3389/fimmu.2017.00524
EID:

2-s2.0-85020011170
Contributors: Jazayeri, S.D.; Kuo, P.T.; Leggatt, G.R.; Frazer, I.H.
Source: Self-asserted source
Paula Kuo via Scopus - Elsevier

HPV16E7 Induced Hyperplasia Promotes CXCL9/10 Expression and Induces CXCR3 + T cell Migration to Skin

Journal of Investigative Dermatology
2017-12-23 | Journal article
DOI: 10.1016/j.jid.2017.12.021
Source: Self-asserted source
Paula Kuo
grade
Preferred source (of 2)‎

A Mouse Model of Hyperproliferative Human Epithelium Validated by Keratin Profiling Shows an Aberrant Cytoskeletal Response to Injury

EBioMedicine
2016 | Journal article
DOI: 10.1016/j.ebiom.2016.06.011
EID:

2-s2.0-84991628180
Contributors: Zhussupbekova, S.; Sinha, R.; Kuo, P.; Lambert, P.F.; Frazer, I.H.; Tuong, Z.K.
Source: Self-asserted source
Paula Kuo via Scopus - Elsevier

Hedgehog pathway maintains cell survival under stress conditions, and drives drug resistance in lung adenocarcinoma

Oncotarget
2016 | Journal article
DOI: 10.18632/oncotarget.8253
EID:

2-s2.0-84966570027
Contributors: Lin, E.-H.; Kao, Y.-R.; Lin, C.-A.; Kuo, T.-Y.; Yang, S.-P.; Hsu, C.-F.; Chou, T.-Y.; Ho, C.-C.; Wu, C.-W.
Source: Self-asserted source
Paula Kuo via Scopus - Elsevier
How many people are using ORCID?